Abhishek Tiwari, Consultant Medical Oncologist at Regency Health, shared a post on LinkedIn:
“I am happy to share that I had the opportunity to present our research work at the European Lung Cancer Congress (ELCC) 2026 in Copenhagen, Denmark.
Our study was a multi-institutional real-world analysis focusing on TP53 co-mutations in EGFR-mutant lung cancer and their impact on treatment outcomes. We found that patients with TP53 co-mutations had lower response rates, shorter progression-free survival, and higher chances of early treatment failure, indicating a more aggressive disease biology.
What made this particularly interesting was that at the same conference, another well planned study (TOP study) showed that EGFR-mutant patients with TP53 mutations had better outcomes when treated with Osimertinib plus chemotherapy compared to Osimertinib alone. This suggests that TP53 co-mutation may identify a high-risk group where combination therapy may be a better first-line strategy.
It was a great learning experience to see how real-world data and clinical trials from different parts of the world are pointing in the same direction toward more personalized treatment approaches in lung cancer.
Grateful for the opportunity to present, learn, and contribute to the field of thoracic oncology.”
Other articles about ELCC 2026 on OncoDaily.
